CRDL
Cardiol Therapeutics Inc.
Company Overview
| Mkt Cap | $101.53M | Price | $0.97 |
| Volume | 274.04K | Change | +0.83% |
| P/E Ratio | -2.8 | Open | $0.98 |
| Revenue | -- | Prev Close | $0.97 |
| Net Income | $-36.7M | 52W Range | $0.77 - $1.67 |
| Div Yield | N/A | Target | $8.50 |
| Overall | 38 | Value | 40 |
| Quality | -- | Technical | 36 |
No chart data available
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Latest News
Cardiol Therapeutics’ Phase-3 Trial: A Potential Game-Changer in Recurrent Pericarditis Treatment
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRDL | $0.97 | +0.8% | 274.04K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cardiol Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW